Nuvectis Pharma (NVCT) Free Cash Flow (2021 - 2026)
Nuvectis Pharma (NVCT) reported Free Cash Flow of -$6.5 million for Q1 2026, down 55.99% on a YoY basis from -$14.8 million in Q1 2025, and down 63.84% sequentially from -$4.0 million in Q4 2025.
Nuvectis Pharma (NVCT) Free Cash Flow (2021 - 2026) Analysis & Trends
Nuvectis Pharma (NVCT) has 6 years of Free Cash Flow data on file, last reported at -$6.5 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 55.99% year-over-year to -$6.5 million; the trailing twelve-month figure through Mar 2026 stood at -$18.3 million (down 52.08% YoY), and the FY2025 full-year result was -$16.0 million, down 30.72% from the prior year.
- Free Cash Flow slipped to -$6.5 million in Q1 2026, from -$4.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$2.4 million in Q3 2024 to a low of -$6.5 million in Q1 2026.
- A 5-year average of -$3.8 million and a median of -$3.8 million in 2023 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow sank 229.52% in 2022 and jumped 35.97% in 2024, its largest moves.
- Tracing NVCT's Free Cash Flow over 5 years: stood at -$3.5 million in 2022, then decreased by 9.5% to -$3.8 million in 2023, then surged by 35.97% to -$2.5 million in 2024, then slumped by 61.22% to -$4.0 million in 2025, then plunged by 63.84% to -$6.5 million in 2026.
- Business Quant data shows NVCT's Free Cash Flow at -$6.5 million in Q1 2026, -$4.0 million in Q4 2025, and -$4.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 158.09 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -354.95 Mn |
| 10 | Nuvectis Pharma | 453.54 Mn | 453.54 Mn | - | -6.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.51 Mn |
| Mar 31, 2026 | -6.51 Mn |
| Dec 31, 2025 | -3.97 Mn |
| Dec 31, 2025 | -3.97 Mn |
| Sep 30, 2025 | -4.49 Mn |
| Sep 30, 2025 | -4.49 Mn |
| Jun 30, 2025 | -3.37 Mn |
| Jun 30, 2025 | -3.37 Mn |
| Mar 31, 2025 | -4.17 Mn |
| Mar 31, 2025 | -4.17 Mn |
| Dec 31, 2024 | -2.47 Mn |
| Dec 31, 2024 | -2.47 Mn |
| Sep 30, 2024 | -2.40 Mn |
| Sep 30, 2024 | -2.40 Mn |
| Jun 30, 2024 | -3.02 Mn |
| Jun 30, 2024 | -3.02 Mn |
| Mar 31, 2024 | -4.36 Mn |
| Mar 31, 2024 | -4.36 Mn |
| Dec 31, 2023 | -3.85 Mn |
| Dec 31, 2023 | -3.85 Mn |